Baird Financial Group
AZN icon

Baird Financial Group’s AstraZeneca AZN Stock Holding History

Baird Financial Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.3M Sell
133,378
-667
-0.5% -$129K 0.04% 297
2025
Q4 		$24.6M Sell
134,045
-536
-0.4% -$94K 0.04% 319
2025
Q3 		$20.7M Buy
134,581
+3,179
+2% +$481K 0.03% 371
2025
Q2 		$18.4M Sell
131,402
-1,441
-1% -$202K 0.03% 377
2025
Q1 		$19.5M Buy
132,843
+472
+0.4% +$68.3K 0.04% 356
2024
Q4 		$17.3M Buy
132,371
+7,862
+6% +$1.1M 0.03% 380
2024
Q3 		$19.4M Buy
124,509
+676
+0.5% +$109K 0.04% 341
2024
Q2 		$19.3M Buy
123,833
+3,357
+3% +$505K 0.04% 330
2024
Q1 		$16.3M Buy
120,476
+12,114
+11% +$1.6M 0.03% 369
2023
Q4 		$14.6M Sell
108,362
-6,644
-6% -$864K 0.03% 379
2023
Q3 		$15.6M Buy
115,006
+1,421
+1% +$194K 0.04% 341
2023
Q2 		$16.3M Buy
113,585
+9,142
+9% +$1.35M 0.04% 343
2023
Q1 		$14.5M Buy
104,443
+69,311
+197% +$9.33M 0.04% 359
2022
Q4 		$4.76M Sell
35,132
-852
-2% -$107K 0.01% 588
2022
Q3 		$3.95M Buy
35,984
+1,133
+3% +$144K 0.01% 627
2022
Q2 		$4.61M Sell
34,851
-1,059
-3% -$139K 0.01% 600
2022
Q1 		$4.76M Buy
35,910
+359
+1% +$43.1K 0.01% 629
2021
Q4 		$4.14M Sell
35,551
-645
-2% -$75.9K 0.01% 667
2021
Q3 		$4.35M Buy
36,196
+3,037
+9% +$354K 0.01% 652
2021
Q2 		$3.97M Sell
33,159
-504
-1% -$55.3K 0.01% 676
2021
Q1 		$3.35M Sell
33,663
-24,161
-42% -$2.43M 0.01% 702
2020
Q4 		$5.78M Sell
57,824
-32,324
-36% -$3.42M 0.02% 509
2020
Q3 		$9.88M Buy
90,148
+17,419
+24% +$1.94M 0.03% 365
2020
Q2 		$7.69M Buy
72,729
+26,701
+58% +$2.76M 0.03% 386
2020
Q1 		$4.11M Sell
46,028
-35,914
-44% -$3.38M 0.02% 488
2019
Q4 		$8.17M Buy
81,942
+2,917
+4% +$275K 0.03% 417
2019
Q3 		$7.04M Buy
79,025
+783
+1% +$67.9K 0.03% 427
2019
Q2 		$6.46M Buy
78,242
+52,228
+201% +$4.1M 0.03% 450
2019
Q1 		$2.1M Sell
26,014
-315
-1% -$24.8K 0.01% 648
2018
Q4 		$2M Buy
26,329
+176
+0.7% +$13.7K 0.01% 628
2018
Q3 		$2.07M Sell
26,153
-2,327
-8% -$176K 0.01% 657
2018
Q2 		$2M Buy
28,480
+3,046
+12% +$219K 0.01% 653
2018
Q1 		$1.78M Sell
25,434
-1,129
-4% -$78.2K 0.01% 662
2017
Q4 		$1.84M Sell
26,563
-198
-0.7% -$13.4K 0.01% 653
2017
Q3 		$1.81M Sell
26,761
-686
-2% -$43.3K 0.01% 640
2017
Q2 		$1.87M Buy
27,447
+852
+3% +$55.6K 0.01% 624
2017
Q1 		$1.66M Buy
26,595
+267
+1% +$15.5K 0.01% 639
2016
Q4 		$1.44M Buy
26,328
+459
+2% +$26.1K 0.01% 652
2016
Q3 		$1.7M Sell
25,869
-473
-2% -$30.9K 0.02% 598
2016
Q2 		$1.59M Sell
26,342
-328
-1% -$19.1K 0.01% 612
2016
Q1 		$1.5M Sell
26,670
-3,774
-12% -$227K 0.01% 607
2015
Q4 		$2.07M Buy
30,444
+100
+0.3% +$6.56K 0.02% 518
2015
Q3 		$1.93M Buy
30,344
+1,694
+6% +$111K 0.02% 529
2015
Q2 		$1.82M Buy
+28,650
New +$1.96M 0.02% 579

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Baird Financial Group's AZN Position: Q1 2026 in Review

Baird Financial Group reduced its AstraZeneca (AZN) stake by 0.5% in Q1 2026, selling an estimated $129K and leaving 133,378 shares worth $26.3M. The position accounts for 0.04% of the portfolio, ranked #297.

Baird Financial Group first reported a position in AZN in Q2 2015 and has held it in 44 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Baird Financial Group held 133,378 shares of AstraZeneca worth $26.3M as of Q1 2026.
  • Baird Financial Group sold 667 AstraZeneca shares in Q1 2026, an estimated $129K.
  • AstraZeneca made up 0.04% of Baird Financial Group's portfolio in Q1 2026, its #297 holding.
  • Baird Financial Group first reported a position in AstraZeneca in Q2 2015 and has held it in 44 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Baird Financial Group's 13F filing for Q1 2026, filed 14 May 2026.